Gund Vision Fund focuses on mission-related investments to rapidly drive research into preventions, treatments and cures for blinding retinal diseases.
Joined November 2018
- Tweets437
- Following172
- Followers154
- Likes136
Opus Genetics announced that the U.S. FDA has cleared its IND application for OPGx-RDH12, an investigational gene therapy for the treatment of RDH12-LCA.
Read more: bit.ly/4BBa2xI
ALT Opus Genetics logo
Perceive Biotherapeutics, Inc. completes enrollment in Phase 2a JOURNEY study of VOY-101 gene therapy for geographic atrophy and appoints Tony Gibney to Board of Directors.
Read more on our website at: bit.ly/4dtGwPX
Atsena Therapeutics presented 18-month safety and efficacy results from Part A of the Phase 1/2/3 LIGHTHOUSE Trial evaluating ATSN-201 in patients with X-linked retinoschisis (XLRS) at the American Academy of Optometry 2026 Annual Meeting.
Read more at: bit.ly/4zuyf75
José-Alain Sahel, MD, Gund Vision Fund Board Member, received the prestigious António Champalimaud Vision Award together with his colleague Botond Roska, MD, PhD, for their work to restore sight using optogenetics.
Read More at: bit.ly/46E2SdO
Beacon Therapeutics announced positive topline results for its registration-enabling VISTA trial evaluating laruparetigene zovaparvovec (laru-zova) in patients with X-linked retinitis pigmentosa (XLRP).
Read more at: bit.ly/4rolIiq
In 2018, the Retinal Degeneration Fund set out to bridge the gap between promising science and the treatments patients need.
Eight years later, that model is proven — and the vision is bigger.
Introducing the Gund Vision Fund.
GundVisionFund.org
Atsena Therapeutics has announced that the European Medicines Agency (EMA) has granted orphan designation to its two clinical-stage gene therapy product candidates being developed for inherited retinal diseases.
Read more at: bit.ly/4fuI3VU
Opus Genetics has provided updates on its ongoing OPGx-BEST1 Phase 1/2 clinical trial (BIRD-1) targeting BEST-1 associated IRDs.
Read more at: bit.ly/4h6Uc5Y
Atsena Therapeutics announced the selection of a lead clinical candidate for ATSN-401, a potential best-in-class gene therapy for Stargardt disease.
Read more at: bit.ly/3Tusnus
Atsena Therapeutics has announced that the first patient has been dosed in the Phase 3 pivotal cohort of the LIGHTHOUSE trial evaluating ATSN-201 for the treatment of X-linked retinoschisis (XLRS).
Read more at: bit.ly/4w3MpKC
The Foundation Fighting Blindness and the RD Fund has announced a $1 million commitment from A Race Against Blindness (RAB) to advance gene-agnostic therapeutic approaches for inherited retinal diseases.
Read more about RAB and their commitment at: bit.ly/4vkVq1Z
Beacon Therapeutics has announced a 12-month safety and efficacy update from its Phase 2 DAWN trial of laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP) at the ARVO Annual Meeting held in Denver, Colorado.
Read more at: bit.ly/4uwH7GA
This week, Atsena Therapeutics presented data from three studies at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Denver, CO.
Read more at: bit.ly/4d0zmD6
Opus Genetics has announced that its investigational LCA5 gene therapy program, OPGx-LCA5, has been accepted into the U.S. Food and Drug Administration’s (FDA) Rare Disease Evidence Principles (RDEP) program.
Read more at: bit.ly/42f6HnC
Atsena Therapeutics receives Data Monitoring Committee recommendation to proceed with pivotal Part C cohort of Phase 1/2/3 LIGHTHOUSE trial evaluating ATSN-201 in patients with X-linked retinoschisis (XLRS).
Read more at: bit.ly/4cw4bhm
Opus Genetics solidifies leadership position in gene therapy development for inherited retinal diseases (IRDs) with strategic long-term financing by Oberland Capital. Read more at bit.ly/41Pzm28
RD Fund portfolio company Opus Genetics reports encouraging Phase 1/2 OPGx-BEST1 data: well tolerated, 12-letter visual acuity gain, 23% reduction in central retinal thickness. Full Cohort 1 results expected mid-2026. retinaldegenerationfund.org/…
The RD Fund community mourns the loss of Karen Petrou, Foundation Fighting Blindness Board Chair and RD Fund Vice Chair, who passed away after a private battle with liver cancer.
Read more about Karen’s legacy on our website: bit.ly/3Oojm3U
RD Fund portfolio company @SparingVision has completed patient dosing in its Phase I/II PRODYGY trial of SPVN06 for retinitis pigmentosa.
This milestone advances the program toward a 2027 data readout. bit.ly/45WpYMR
#GeneTherapy milestone 🧬 Opus Genetics, founded by the RD Fund, has launched a clinical trial for MERTK-related retinitis pigmentosa, a rare inherited retinal disease with no approved treatments. bit.ly/45v1k5F